Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. / Radue, Ernst-Wilhelm; Stuart, William H; Calabresi, Peter A; Confavreux, Christian; Galetta, Steven L; Rudick, Richard A; Lublin, Fred D; Weinstock-Guttman, Bianca; Wynn, Daniel R; Fisher, Elizabeth; Papadopoulou, Athina; Lynn, Frances; Panzara, Michael A; Sandrock, Alfred W; SENTINEL Investigators ; Sørensen, Per Soelberg; Blinkenberg, Morten Bjørn.

I: Journal of the Neurological Sciences, Bind 292, Nr. 1-2, 15.05.2010, s. 28-35.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Radue, E-W, Stuart, WH, Calabresi, PA, Confavreux, C, Galetta, SL, Rudick, RA, Lublin, FD, Weinstock-Guttman, B, Wynn, DR, Fisher, E, Papadopoulou, A, Lynn, F, Panzara, MA, Sandrock, AW, SENTINEL Investigators, Sørensen, PS & Blinkenberg, MB 2010, 'Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis', Journal of the Neurological Sciences, bind 292, nr. 1-2, s. 28-35. https://doi.org/10.1016/j.jns.2010.02.012

APA

Radue, E-W., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Rudick, R. A., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Fisher, E., Papadopoulou, A., Lynn, F., Panzara, M. A., Sandrock, A. W., SENTINEL Investigators, Sørensen, P. S., & Blinkenberg, M. B. (2010). Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 292(1-2), 28-35. https://doi.org/10.1016/j.jns.2010.02.012

Vancouver

Radue E-W, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA o.a. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences. 2010 maj 15;292(1-2):28-35. https://doi.org/10.1016/j.jns.2010.02.012

Author

Radue, Ernst-Wilhelm ; Stuart, William H ; Calabresi, Peter A ; Confavreux, Christian ; Galetta, Steven L ; Rudick, Richard A ; Lublin, Fred D ; Weinstock-Guttman, Bianca ; Wynn, Daniel R ; Fisher, Elizabeth ; Papadopoulou, Athina ; Lynn, Frances ; Panzara, Michael A ; Sandrock, Alfred W ; SENTINEL Investigators ; Sørensen, Per Soelberg ; Blinkenberg, Morten Bjørn. / Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. I: Journal of the Neurological Sciences. 2010 ; Bind 292, Nr. 1-2. s. 28-35.

Bibtex

@article{7a9c464864c84a13a514e9d5dc905885,
title = "Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis",
abstract = "The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p",
author = "Ernst-Wilhelm Radue and Stuart, {William H} and Calabresi, {Peter A} and Christian Confavreux and Galetta, {Steven L} and Rudick, {Richard A} and Lublin, {Fred D} and Bianca Weinstock-Guttman and Wynn, {Daniel R} and Elizabeth Fisher and Athina Papadopoulou and Frances Lynn and Panzara, {Michael A} and Sandrock, {Alfred W} and S{\o}rensen, {Per Soelberg} and S{\o}rensen, {Per Soelberg} and Blinkenberg, {Morten Bj{\o}rn}",
note = "Copyright 2010 Elsevier B.V. All rights reserved.",
year = "2010",
month = may,
day = "15",
doi = "http://dx.doi.org/10.1016/j.jns.2010.02.012",
language = "English",
volume = "292",
pages = "28--35",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

RIS

TY - JOUR

T1 - Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

AU - Radue, Ernst-Wilhelm

AU - Stuart, William H

AU - Calabresi, Peter A

AU - Confavreux, Christian

AU - Galetta, Steven L

AU - Rudick, Richard A

AU - Lublin, Fred D

AU - Weinstock-Guttman, Bianca

AU - Wynn, Daniel R

AU - Fisher, Elizabeth

AU - Papadopoulou, Athina

AU - Lynn, Frances

AU - Panzara, Michael A

AU - Sandrock, Alfred W

AU - SENTINEL Investigators

AU - Sørensen, Per Soelberg

AU - Blinkenberg, Morten Bjørn

N1 - Copyright 2010 Elsevier B.V. All rights reserved.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p

AB - The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p

U2 - http://dx.doi.org/10.1016/j.jns.2010.02.012

DO - http://dx.doi.org/10.1016/j.jns.2010.02.012

M3 - Journal article

VL - 292

SP - 28

EP - 35

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -

ID: 34080487